Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Хронический эндометрит: современные взгляды на проблему
Хронический эндометрит: современные взгляды на проблему
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Корсак, В.С., Забелкина О.В., Исакова Э.В. Исследование эндометрия у пациенток с трубно-перитонеальным бесплодием на этапе подготовки к ЭКО. Проблемы репродукции. 2005; 2: 39–42.
2. Сидельникова В.М. Привычная потеря беременности. М.: Триада-Х, 2000.
3. Сметник В.П., Тумилович Л.Г. Неоперативная гинекология: руководство для врачей. М.: МИА, 2002.
4. Buckley CH, Fox H. Biopsy pathology of the endometrium. NY: Arnold, 2002.
5. Шуршалина А.В. Хронический эндометрит. Автореф. дис. ... д-ра мед. наук. М., 2007.
6. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. Morbidity and Mortality Weekly Report (MMWR) 2010; 59 (RR-12): 1–114.
7. Демидов В.Н., Гус А.И. Эхография органов малого таза у женщин. Вып. III. Патология полости матки и эндометрия. ВМК: практ. пособие. М., 2000; с. 16–36.
8. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertil Steril 1950; 1: 3–25.
9. Novak ER,Woodruff JD. Gynecologic and obstetric pathology. Philadelphia 1999; 241–5.
10. Ness RB, Soper DE, Holley RL. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002; 186 (5): 929–37.
11. Стругацкий В.М., Силантьева Е.С. Акуш. и гинекол. 2002; 6: 51–3.
12. Haggerty CL, Ness RB. Diagnosis and treatment of pelvic inflammatory disease. Womens Health (Lond Engl) 2008; 4 (4): 383–97.
13. Morikawa K, Zhang J, Nonaka M, Morikawa S. Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production. Int J Antimicrob Agents 2002; 19 (1): 53–9.
14. Bradshaw CS, Chen MY, Fairley CK. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS ONE 2008; 3 (11): e3618.
15. Bjartling C, Osser S, Persson K. The association between Mycoplasma genitalium and pelvic inflammatory disease after termination of pregnancy. Bjog 2010; 117 (3): 361–4.
16. Jaiyeoba O, Lazenby G, Soper DE. Recommendations and rationale for the treatment of pelvic inflammatory disease. Expert review of anti-infective therapy 2011; 9 (1): 61–70.
17. Bhengraj AR, Vardhan H, Srivastava P, Salhan S et al. Decreased Susceptibility to Azithromycin and Doxycycline in Clinical Isolates of Chlamydia trachomatis Obtained from Recurrently Infected Female Patients in India. Chemotherapy 2010; 56 (5): 371–7.
18. Sternak SL, Skerk V. [Determining antimicrobial resistance to Chlamydia trachomatis and applying present findings in daily practice]. Med Glas Ljek komore Zenicko-doboj kantona 2010; 7 (1): 26–31.
19. Segreti J, Kapell KS, Trenholme GM. In vitro activity of beta-lactam drugs and sulbactam against Chlamydia trachomatis. Diagnostic microbiology and infectious disease 1992; 15 (4): 371–3.
20. Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta obstetricia et gynecologica Scandinavica 2000; 79 (3): 234–7.
21. Oshima T, Iwadare M. Josamycin propionate. 5. Teratological studies. The Japanese journal of antibiotics 1973; 26 (2): 148–53.
22. Ikezaki S, Nishikawa A, Furukawa F et al. A 13-week subchronic toxicity study of josamycin in F344 rats. Eisei Shikenjo Hokoku 1995; (113): 44–50.
23. Miura M, Morino T, Endo H, Shiraiwa K et al. Comparative toxicity study of rokitamycin and josamycin in rats. Jpn J Antibiot 1987; 40 (3): 588–601.
24. Kuriaki K, Miki H, Sejima Y, Shibata M et al. New antibiotics, Josamycin. V. Studies on toxicity of Josamycin. Jpn J Antibiot 1969; 22 (3): 219–25.
25. Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy – 15 years experience of ENTIS. Reproductive toxicology. Elmsford. NY, 2005; 20 (3): 331–43.
2. Сидельникова В.М. Привычная потеря беременности. М.: Триада-Х, 2000.
3. Сметник В.П., Тумилович Л.Г. Неоперативная гинекология: руководство для врачей. М.: МИА, 2002.
4. Buckley CH, Fox H. Biopsy pathology of the endometrium. NY: Arnold, 2002.
5. Шуршалина А.В. Хронический эндометрит. Автореф. дис. ... д-ра мед. наук. М., 2007.
6. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. Morbidity and Mortality Weekly Report (MMWR) 2010; 59 (RR-12): 1–114.
7. Демидов В.Н., Гус А.И. Эхография органов малого таза у женщин. Вып. III. Патология полости матки и эндометрия. ВМК: практ. пособие. М., 2000; с. 16–36.
8. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertil Steril 1950; 1: 3–25.
9. Novak ER,Woodruff JD. Gynecologic and obstetric pathology. Philadelphia 1999; 241–5.
10. Ness RB, Soper DE, Holley RL. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002; 186 (5): 929–37.
11. Стругацкий В.М., Силантьева Е.С. Акуш. и гинекол. 2002; 6: 51–3.
12. Haggerty CL, Ness RB. Diagnosis and treatment of pelvic inflammatory disease. Womens Health (Lond Engl) 2008; 4 (4): 383–97.
13. Morikawa K, Zhang J, Nonaka M, Morikawa S. Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production. Int J Antimicrob Agents 2002; 19 (1): 53–9.
14. Bradshaw CS, Chen MY, Fairley CK. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS ONE 2008; 3 (11): e3618.
15. Bjartling C, Osser S, Persson K. The association between Mycoplasma genitalium and pelvic inflammatory disease after termination of pregnancy. Bjog 2010; 117 (3): 361–4.
16. Jaiyeoba O, Lazenby G, Soper DE. Recommendations and rationale for the treatment of pelvic inflammatory disease. Expert review of anti-infective therapy 2011; 9 (1): 61–70.
17. Bhengraj AR, Vardhan H, Srivastava P, Salhan S et al. Decreased Susceptibility to Azithromycin and Doxycycline in Clinical Isolates of Chlamydia trachomatis Obtained from Recurrently Infected Female Patients in India. Chemotherapy 2010; 56 (5): 371–7.
18. Sternak SL, Skerk V. [Determining antimicrobial resistance to Chlamydia trachomatis and applying present findings in daily practice]. Med Glas Ljek komore Zenicko-doboj kantona 2010; 7 (1): 26–31.
19. Segreti J, Kapell KS, Trenholme GM. In vitro activity of beta-lactam drugs and sulbactam against Chlamydia trachomatis. Diagnostic microbiology and infectious disease 1992; 15 (4): 371–3.
20. Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta obstetricia et gynecologica Scandinavica 2000; 79 (3): 234–7.
21. Oshima T, Iwadare M. Josamycin propionate. 5. Teratological studies. The Japanese journal of antibiotics 1973; 26 (2): 148–53.
22. Ikezaki S, Nishikawa A, Furukawa F et al. A 13-week subchronic toxicity study of josamycin in F344 rats. Eisei Shikenjo Hokoku 1995; (113): 44–50.
23. Miura M, Morino T, Endo H, Shiraiwa K et al. Comparative toxicity study of rokitamycin and josamycin in rats. Jpn J Antibiot 1987; 40 (3): 588–601.
24. Kuriaki K, Miki H, Sejima Y, Shibata M et al. New antibiotics, Josamycin. V. Studies on toxicity of Josamycin. Jpn J Antibiot 1969; 22 (3): 219–25.
25. Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy – 15 years experience of ENTIS. Reproductive toxicology. Elmsford. NY, 2005; 20 (3): 331–43.
Авторы
А.В.Шуршалина
Американский медицинский центр, Москва
Американский медицинский центр, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.